




The importance of animal models in understanding cell-to-cell propagation of prions and prionoids


Transcellular propagation of prions and prionoids

- **Definition:** process by which a specific amyloid structure grows within a cell, followed by its movement to a second cell and its subsequent amplification there based on interactions with the native protein
- **Timeline:**




- **Relevance:** multiple lines of evidence have pointed to cell-to-cell propagation of amyloids to play a key role in the progression of multiple neurological diseases

Potential mechanisms driving prion & prionoid transcellular propagation



Modified from Vaquer-Alicea et Diamond, 2019, Annual Review of Biochemistry

Potential mechanisms driving prion & prionoid transcellular propagation



Why do we need to use animal models?

Cellular models



Indispensable to achieve a first, basic understanding of the mechanisms of disease



Comparatively easy and cheap to work with vs animal models



Cannot begin to truly reproduce the pathophysiological processes that takes place in living beings

Animal models



Much more laborious to generate, maintain and study



They provide a complete physiological system




They can (partly) reproduce the hallmarks of disease



Necessary to corroborate the findings made in cellular models

Employed animal models




Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons


Eline Pecho-Vrieseling^{1,5}, Claus Rieker^{1,5}, Sascha Fuchs¹, Dorothee Bleckmann¹, Maria Soledad Esposito^{2,3}, Paolo Botta², Chris Goldstein¹, Mario Bernhard¹, Ivan Galimberti¹, Matthias Müller¹, Andreas Lüthi², Silvia Arber^{2,3}, Tewis Bouwmeester¹, Herman van der Putten^{1,4} & Francesco Paolo Di Giorgio¹

Functional integration of hESC-derived neurons in mouse OTBSs



a




b




c





hGFP neurons exhibit non-cell autonomous pathology in R6/2 OTBSs




hGFP neurons exhibit non-cell autonomous pathology in R6/2 OTBSs





mHTT aggregate pathology spreads from R6/2 OTBSs to hGFP neurons






mHTT aggregate pathology spreads from R6/2 OTBSs to hGFP neurons




mHTT aggregate pathology spreads from R6/2 OTBSs to hGFP neurons




mHTT aggregate pathology spreads to hGFP neurons *in vivo*




Cellular atrophy is associated with the presence of mHTT



mHTT transneuronal propagation in the corticostriatal pathway




mHTT transneuronal propagation in the corticostriatal pathway





mHTT transneuronal propagation in the corticostriatal pathway *in vivo*

Synaptophysin-GFP/Q72-Htt-Exon1/DARPP-32/DAPI






mHTT transneuronal propagation in the corticostriatal pathway *in vivo*

Synaptophysin-GFP/Q72-Htt-Exon1/DARPP-32/DAPI



Inhibitors of synaptic vesicle fusion block propagation of mHTT



Main conclusions

- Transneuronal propagation of mHTT protein pathology occurs in neuronal networks, both *ex vivo* and *in vivo*
- Spreading was found to affect neural integrity
- Spreading was largely blocked by treatment with BoNTs, known to interfere with synaptic vesicle fusion
- **This leads to believe that transneuronal propagation of mHTT likely acts as a contributor to neuronal pathology in HD**

DOI: 10.1002/alz.12318


FEATURED ARTICLE

Alzheimer's & Dementia®
THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION


A novel tau-based rhesus monkey model of Alzheimer's pathogenesis

Danielle Beckman¹ | Paramita Chakrabarty² | Sean Ott¹ | Amanda Dao¹ |
Eric Zhou¹ | William G. Janssen³ | Kristine Donis-Cox¹ | Scott Muller⁴ |
Jeffrey H. Kordower^{4,6} | John H. Morrison^{1,5} 


Injected monkeys develop AD core biomarkers in CSF and plasma




Injected monkeys develop AD core biomarkers in CSF and plasma




Injected monkeys develop AD core biomarkers in CSF and plasma




AAV-2xTau injection in the ERC induces extensive tau pathology in the hippocampus




AAV-2xTau injection in the ERC induces extensive tau pathology in the hippocampus




Misfolded tau propagation in the hippocampus induces an extensive microglial response




AAV-2xTau injection in the ERC induces extensive tau pathology in the hippocampus



Presence of 4R human tau templates 3R monkey tau to induce propagation



Tau seeds propagate outside ERC-hippocampus in a prion-like manner



Main conclusions

- The development of an AD monkey model with accelerated tau pathology and neuroinflammation allows the study of end-stage NFT tangle development in AD vulnerable areas such as the ERC and hippocampus, as well as tau phosphorylation in regions several synaptic connections away from the site of injection only 3 months after injection
- They confirm the ability of human 4R tau to self-propagate inside the monkey brain via permissive templating of endogenous 3R tau
- **The development of NHP models of AD (and neurodegeneration broadly) can help us close the translational gap between mouse models and human clinical trials**

Thank you very much for your attention!



